Publication Name	World Journal of Nephrology
Manuscript ID	98393
Country	Russia

Received	2024-06-25 12:58
Peer-Review Started	2024-06-25 12:58
To Make the First Decision
Return for Revision	2024-08-14 05:14
Revised	2024-08-23 07:29
Second Decision	2024-09-05 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-05 09:34
Articles in Press	2024-09-05 09:34
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-09-21 21:00
Typeset the Manuscript	2024-10-16 02:41
Publish the Manuscript Online	2024-11-07 08:48

ISSN	2220-6124 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pediatrics
Manuscript Type	Retrospective Study
Article Title	Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study
Manuscript Source	Invited Manuscript
All Author List	Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Natalia Lubimova, Lyubov Sorokina, Irina Chikova, Maria Kaneva, Rinat Raupov, Olga Kalashnikova, Damir Aliev, Inna Gaydukova and Mikhail Kostik
ORCID	Author(s) ORCID Number Elvira Kalashnikova http://orcid.org/0000-0002-4932-0588 Eugenia Isupova http://orcid.org/0000-0002-0911-7817 Ekaterina Gaidar http://orcid.org/0000-0002-0971-2018 Natalia Lubimova http://orcid.org/0000-0002-5782-8373 Lyubov Sorokina http://orcid.org/0000-0002-9710-9277 Irina Chikova http://orcid.org/0000-0003-4636-5825 Maria Kaneva http://orcid.org/0000-0003-4325-0125 Rinat Raupov http://orcid.org/0000-0001-7749-6663 Olga Kalashnikova http://orcid.org/0000-0002-8683-4270 Damir Aliev http://orcid.org/0000-0001-8367-4622 Inna Gaydukova http://orcid.org/0000-0003-3500-7256 Mikhail Kostik http://orcid.org/0000-0002-1180-8086
Funding Agency and Grant Number	Funding Agency Grant Number Ministry of Science and Higher Education of the Russian Federation 075-15-2022-301 Russian Science Foundation 22-45-08004
Corresponding Author	Mikhail Kostik, MD, PhD, Professor, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint Petersburg 194100, Sankt-Peterburg, Russia. kost-mikhail@yandex.ru
Key Words	Systemic lupus erythematosus; Rituximab; Rituximab BCD020 biosimilar; Anti-CD-20; Biologic; Children
Core Tip	Systemic lupus erythematosus in children is a severe life-threatening disease, that requires systemic immune-suppressive therapy. Early biologic treatment in children with systemic lupus erythematosus can provide faster remission with a better corticosteroid-sparing effect.
Publish Date	2024-11-07 08:48
Citation	<p>Kalashnikova E, Isupova E, Gaidar E, Lubimova N, Sorokina L, Chikova I, Kaneva M, Raupov R, Kalashnikova O, Aliev D, Gaydukova I, Kostik M. Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study. <i>World J Nephrol</i> 2024; 13(4): 98393</p>
URL	https://www.wjgnet.com/2220-6124/full/v13/i4/98393.htm
DOI	https://dx.doi.org/10.5527/wjn.v13.i4.98393

Full Article (PDF)	WJN-13-98393-with-cover.pdf
Manuscript File	98393_Auto_Edited_034918.docx
Answering Reviewers	98393-answering-reviewers.pdf
Audio Core Tip	98393-audio.m4a
Biostatistics Review Certificate	98393-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	98393-conflict-of-interest-statement.pdf
Copyright License Agreement	98393-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	98393-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	98393-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	98393-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	98393-non-native-speakers.pdf
Peer-review Report	98393-peer-reviews.pdf
Scientific Misconduct Check	98393-scientific-misconduct-check.png
Scientific Editor Work List	98393-scientific-editor-work-list.pdf
CrossCheck Report	98393-crosscheck-report.pdf
CrossCheck Report	98393-crosscheck-report.png